Russell Investments Group Ltd. Purchases 36,776 Shares of Thermo Fisher Scientific Inc. $TMO

Russell Investments Group Ltd. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 282,542 shares of the medical research company’s stock after acquiring an additional 36,776 shares during the quarter. Russell Investments Group Ltd.’s holdings in Thermo Fisher Scientific were worth $163,885,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in TMO. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at about $170,000. Raymond James Financial Inc. grew its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its position in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after buying an additional 2,262 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on TMO shares. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. Finally, Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $472.73 on Wednesday. The company has a market cap of $175.68 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.10 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm’s 50-day simple moving average is $478.34 and its two-hundred day simple moving average is $525.54.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.